PET Imaging of P-glycoprotein Function Using [11C]dLop
NCT00605254 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58
Last updated 2019-12-17
Summary
This study will test the use of a radioactive substance called \[11C\]dLop for measuring P-glycoprotein (P-gp) using positron emission tomography (PET) imaging. The P-gp protein acts as a pump in cells, affecting a variety of functions, such as limiting drug absorption and elimination and decreasing drug penetration into certain tissues, such as the brain. It is a major obstacle to successful chemotherapy because it can pump cancer drugs out of the cells, interfering with treatment. Decreased P-gp function may contribute to disorders such as Parkinson s disease and Alzheimer s disease, whereas higher levels of the protein have been found in patients with epilepsy and in several forms of drug-resistant cancer tumors. This study will determine uptake and clearance of \[11C\]dLop and the radiation exposure to organs of the body to assess its possible use in further studies of P-gp function.
Healthy normal volunteers between 18 and 51 years of age may be eligible for this study. Candidates are screened with a medical history, physical examination and blood and urine tests.
Participants undergo the following procedures:
* Electrocardiogram (ECG): A test of the electrical function of the heart.
* Brain PET scans: PET imaging uses small amounts of a radioactive chemical called a tracer that labels active areas of the brain so the activity can be seen with a special camera. The tracer used in this study is \[18F\]FMPEP-d(2). Before starting the scan, a catheter (plastic tube) is placed in a vein in the arm to inject the tracer and another catheter is placed in an artery in the wrist to obtain blood samples during the scan. For the procedure, the subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the person s head still during the scan so the images will be clear. A brief scan is done just before the tracer is injected to provide measures of the brain that are helpful in calculating information from subsequent scans. After the tracer is injected, pictures are taken for about 2.5 hours, while the subject lies still on the scanner bed. Blood and urine tests are done after 24 hours after the scan.
* Magnetic resonance imaging (MRI): An MRI scan is done within 1 year (before or after) of the PET scan. This procedure uses a magnetic field and radio waves to produce images of the brain. The subject lies on a table that is moved into the scanner (a tube-like device), wearing earplugs to muffle the noise of the machine during the scanning process. The test takes about 1 hour....
Conditions
- Healthy
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Principal Investigators
-
William C Kreisl, M.D. · National Institute of Mental Health (NIMH)
Eligibility
- Min Age
- 18 Years
- Max Age
- 51 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-01-24
- Completion
- 2014-09-04
Countries
- United States
Study Locations
More Related Trials
-
P-glycoprotein Function in Brain Diseases
NCT00677885 ·Status: COMPLETED
-
Phase 1 Test-retest Evaluation of [18F]MNI-958 PET
NCT03545789 ·Status: COMPLETED ·Phase: PHASE1
-
Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066
NCT00686504 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
NCT02531360 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Imaging of Brain Amyloid Using [11C]MeS-IMPY
NCT00407576 ·Status: COMPLETED ·Phase: PHASE1
-
[18F]MC225-PET in Neurodegenerative Disease
NCT05853471 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
NCT07348276 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
PET Tau - Neurodegenerative Disease Imaging
NCT03143374 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Normal Binding of R-[11C]PK11195 in Human Subjects
NCT00205595 ·Status: UNKNOWN ·Phase: PHASE1
-
PET Imaging of Peripheral Benzodiazepine Receptors
NCT00696371 ·Status: COMPLETED
-
PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers
NCT01826110 ·Status: COMPLETED ·Phase: PHASE1
-
Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers
NCT06874205 ·Status: RECRUITING ·Phase: PHASE1
-
PET Study to Evaluate Brain Receptor Occupancy, Safety and Pharmacokinetics of ITI-1284 in Healthy Subjects
NCT06299410 ·Status: RECRUITING ·Phase: PHASE1
-
PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP
NCT00598390 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279
NCT02169973 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
NCT05456503 ·Status: RECRUITING ·Phase: PHASE3
-
Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
NCT01165554 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain
NCT01896843 ·Status: COMPLETED ·Phase: PHASE1
-
Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI
NCT04251130 ·Status: ACTIVE_NOT_RECRUITING
-
Translocator Protein and Inflammation After Traumatic Brain Injury
NCT01547780 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of a Novel PET Radioligand to Image OGA
NCT03632226 ·Status: COMPLETED
-
Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers
NCT02167594 ·Status: COMPLETED ·Phase: PHASE1
-
A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density
NCT03577262 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People
NCT02147392 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
NCT03958630 ·Status: TERMINATED ·Phase: PHASE1